Our results along with the relevance of lipid metabolism in the pathogenesis of TB and Mtb survival, as well as the fact that PPARγ deletion in pulmonary Mfs improved the course of murine tuberculosis (52), provide no evidence to think about the potential use of a PPARγ agonist in TB. The gene discussed is PPARG; the disease is tuberculosis.